Virax Biolabs (VRAX) Non-Current Assets (2023 - 2026)
Virax Biolabs (VRAX) posted quarterly Non-Current Assets of $1.5 million for Q1 2026, down 2.42% year-over-year from $1.5 million in Q1 2025, and down 2.42% quarter-over-quarter from $1.5 million in Q1 2025.
Virax Biolabs (VRAX) Non-Current Assets (2023 - 2026) Analysis & Trends
Virax Biolabs' Non-Current Assets history runs 4 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 2.42% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 2.42% YoY), while the FY2026 annual figure was $1.5 million, down 2.42% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.5 million, down from $1.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $1.5 million in Q1 2025, with the low at $178403.0 in Q1 2023.
- The 4-year median for Non-Current Assets is $1.3 million (2024), against an average of $1.1 million.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets surged 518.67% in 2024, then declined 2.42% in 2026.
- Virax Biolabs' Non-Current Assets stood at $178403.0 in 2023, then soared by 518.67% to $1.1 million in 2024, then soared by 38.92% to $1.5 million in 2025, then decreased by 2.42% to $1.5 million in 2026.
- Business Quant data shows VRAX's Non-Current Assets at $1.5 million in Q1 2026, $1.5 million in Q1 2025, and $1.1 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Mar 31, 2023 | 178,403.00 |